NÖNilüfer Aylin Acet Öztürk

Nilüfer Aylin Acet Öztürk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nilüfer Aylin Acet Öztürk has a total of 219 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validity of S3-NIV questionnaire for COPD patients with home non-invasive ventilation, in a Turkish population

    by Nilüfer Aylin Acet-Öztürk, Özge Aydın Güçlü, Gökhan Ocakoğlu, Mihriban Bozkurt Toksun, Samira Süleymanova, Ezgi Demirdöğen, Aslı Görek Dilektaşlı, Funda Coşkun, Ahmet Ursavaş, Esra Uzaslan, et al.

  • Open Access

    Clinical outcomes and prognostic factors in hematologic malignancy patients with probable CMV pneumonia

    by Özge Aydın Güçlü, Ezgi Demirdöğen, Fazıl Çağrı Hunutlu, Merve Nur Yıldız, Nilüfer Aylin Acet Öztürk, Aslı Görek Dilektaşlı, Esra Kazak, Vildan Gürsoy, Tuba Ersal, İmran Sağlık, et al.

  • Open Access

    When Erdheim-Chester disease reaches the pectoral muscle

    by Nele Carton, Nilüfer Aylin Acet Öztürk, Mine Özşen, Özge Aydın-Güçlü, Ahmet Ursavaş

    Erdheim-Chester disease (ECD) is a rare histiocytic disorder. The underlying etiology has not yet been fully elucidated. Recent technological and molecular advances have identified aberrant activation of the MAPK/ERK signalling pathway as a central driver of disease, leading to its reclassification as a neoplastic entity rather than solely a multisystem fibroinflammatory condition. These insights have significantly advanced the understanding of disease pathogenesis and are fundamental to the development and implementation of targeted therapeutic strategies. We describe a case of KRAS-mutant ECD with pleural, pericardial, diaphragmatic, and pectoral muscle involvement in a patient with a prior hematologic history. The disease was refractory to corticosteroid therapy, prompting escalation to second-line treatment with a MEK inhibitor.

  • In-Hospital Mortality Among Hematological Malignancy Patients Undergoing Bronchoscopy for Suspected Invasive Pulmonary Aspergillosis: Focusing on Coinfections and Nodules on Chest CT

    by N. A. Acet-Öztürk, D. Ömer-Topçu, K. V. Acar, Ö. Aydın-Güçlü, İ. E. Pınar, E. Demirdöğen, A. Görek-Dilektaşlı, E. Kazak, V. Özkocaman, A. Ursavas, et al.

    Introduction Invasive pulmonary aspergillosis (IPA) in hematological malignancy populations has high mortality rates. While there are identified prognostic factors for mortality, conflicting results are reported from the studies including bronchoalveolar lavage galactomannan (GM) measurements and co-infections. We aimed to evaluate risk factors associated with in-hospital mortality in a hematological malignancy population undergoing bronchoscopy with a preliminary diagnosis of IPA in a single tertiary care center. Method Patients undergoing bronchoscopy with a preliminary diagnosis of IPA were included in this retrospective study. Bacterial co-infection was defined as a positive bacterial culture in respiratory samples within ± 7 days of the index bronchoscopy procedure. Results Study population consisted 305 patients diagnosed as possible, probable or proven IPA. 57 patients presented with fungal and bacterial co-infection. In-hospital mortality was observed in 98 (33.6%) patients. Patients with mortality status were older and were not in remission for hematological malignancy. Serum GM, bronchoalveolar lavage (BAL) GM and bronchial lavage (BL) GM levels showed a significant relation with in-hospital mortality but weak accuracy. In multivariate analysis for risk factors of in-hospital mortality; age, remission status, number of nodules in HRCT and having fungal infections with or without combined bacterial infection were independent risk factors. Conclusion Co-infections in this susceptible population should not be overlooked even in the presence of fungal infection evidence. BAL and BL GM tended to have a stronger relation with survival than serum GM measurements taken at the same time. The number of nodules in radiological assessment might be an indicator of mortality. Radiological changes through the disease course might be assessed in further studies.


  • Open Access

    Home Spirometry for Post-COVID Recovery: A Clinical Validation Study of an Ultrasonic Device

    by Asli Gorek Dilektasli, Ayten Odabas, Ismet Polat, Abdurrahman Dogan, Guven Ozkaya, Ozge Aydin Guclu, Nilufer Aylin Acet Ozturk, Funda Coskun, Mehmet Karadag

    Background/Objectives: Patients recovering from COVID-19 often experience persistent respiratory symptoms, necessitating pulmonary function monitoring. While clinical spirometry is the gold standard, home spirometry offers a remote alternative. This study evaluated the validity of an ultrasonic home-based spirometer for monitoring lung function in post-COVID-19 pneumonia patients over 12 weeks. Methods: This prospective study included 30 post-COVID pneumonia patients who underwent clinical spirometry at weeks 4, 8 and 12. Participants performed weekly home spirometry using the SpiroHome Personal® device. Agreement between home and clinical spirometry was assessed using a Bland–Altman analysis, intraclass correlation coefficients (ICCs), and Pearson correlation coefficients. Pulmonary function changes over time were analyzed using repeated measures ANOVA. Results: Home spirometry showed strong agreement with clinical spirometry for forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1), with ICC values exceeding 0.92. The Bland–Altman analysis demonstrated minimal bias, though limits of agreement exceeded the clinically accepted threshold of ±150 mL. FEV1/FVC ratios showed greater variability. Pulmonary function improved significantly over 12 weeks for both methods (p < 0.002). Patient adherence to home spirometry remained high, with a median of 18.50 sessions [IQR: 15.00–26.00] and an overall compliance rate of 98.33% ± 9.13%. Conclusions: Home spirometry provides reliable pulmonary function measurements, particularly for FVC and FEV1, supporting its role as a remote monitoring tool. Despite minor variability in FEV1/FVC, home spirometry enables frequent assessment of lung function recovery, potentially reducing hospital visits and improving patient management.

  • Open Access

    Slow gait speed is associated with frailty, activities of daily living and nutritional status in in-patient pulmonology patients

    by Asli Gorek Dilektasli, Nilüfer Aylin Acet Öztürk, Demet Kerimoğlu, Ayten Odabaş, Mine Tül Yaman, Abdurrahman Dogan, Ezgi Demirdogen, Ozge Aydın Guclu, Funda Coşkun, Ahmet Ursavas, et al.

    Background and aim The 4-meter gait speed (4MGS), a functional performance test, is increasingly used to predict health outcomes. This study investigated 4MGS, nutritional status, frailty, and daily living activities in tertiary care pulmonary diseases ward patients. Methods Patients were assessed for nutritional status, activities of daily living, and frailty using the Mini Nutritional Assessment (MNA) Test, Barthel Questionnaire, and FRAIL scale. Those with 4MGS < 1 m/sec were classified as having slow gait speed. Results 80 patients (F/M: 21/59, mean age 58 ± 19) were included. Diagnoses included pneumonia, chronic obstructive pulmonary disease, pleural effusion, and interstitial lung disease. Patients had a 4MGS of 0,74 ± 0,24 m/sn, MNA score of 14.0 [IQR 25–75:11.0–19.8] points, Barthel index of 95 [IQR 25–75:70–100] points, FRAIL scale of 3 [IQR 25–75:1.0–4.0], and a hand-grip strength of 18.8 [IQR 25–75:15.7–25.9] kg. Slow gait speed patients had lower MNA, FRAIL scores, and handgrip strength. Multivariable regression analysis showed that slower gait speed was associated with lower serum protein level (B = 0.013, SE = 0.005, 95% CI: 0.004 to 0.022, p = 0.004), lower hand grip strength (B = -0.002, SE = 0.001, 95% CI: -0.003 to -0.00006, p = 0.041) and malnutrition risk (B = 0.024, SE = 0.007, 95% CI: 0.011 to 0.038, p < 0.001). Discussion and conclusion 4MGS correlates with comorbidities, frailty, grip strength, and nutritional status in hospitalized pulmonary patients. Slow gait patients are more malnourished despite similar age, sex, BMI, and comorbidities.


  • Open Access

    Clinical predictors for restrictive allograft syndrome: A nested case-control study

    by Hanne Beeckmans, Pieterjan Kerckhof, Nilufer Acet Öztürk, Andrea Zajacova, Jan Van Slambrouck, Saskia Bos, Marie Vermant, Lyne O. Van Dieren, Tessa Goeminne, Christelle Vandervelde, et al.


  • Open Access

    Biyolojik Tedavi Alan Hastalarımızda Aktif Tüberküloz

    by Asli Gorek Dilektasli, Belkis Nihan Coskun, Mine Tül Yaman, Nilüfer Aylin Acet-Öztürk, Özge Aydın Güçlü, Ahmet Ursavaş, Ezgi Demirdöğen, Funda Coşkun, Hüseyin Ediz Dalkılıç, Tülay Bulut, et al.

    Biyolojik tedaviler, özellikle latent tüberküloz enfeksiyonu gibi fırsatçı enfeksiyonlar için önemli bir risk faktörüdür. Bu araştırmada, Bursa Uludağ Üniversitesi Sağlık Uygulama ve Araştırma Merkezinde biyolojik ajan tedavisi alan hastalarda aktif tüberküloz hastalığı gelişme sıklığı ve aktif tüberküloz saptanan olguların klinik özelliklerinin değerlendirilmesi amaçlandı. Hastanemizde Romatoloji Bilim dalında Ocak 2010 ve Ocak 2023 tarihleri arasında, farklı tanılarla biyolojik ajanlar ile tedavi alan hastalar geriye dönük olarak incelendi. Tüberküloz tanısı alan hastaların semptom ve fizik muayene bulguları, tüberkülin cilt testleri, koruyucu tedavi alma durumları değerlendirildi. Romatoid artrit, juvenil romatoid artrit, ankilozan spondilit, psöriatik artrit, Behçet hastalığı, eozinofilik granülomatöz polianjitis veya Still hastalığı tanısı bulunan ve biyolojik ajan tedavisi alan toplam 2524 hasta dosyası geriye dönük incelendi. Toplam 13 (% 0,51) hastada aktif tüberküloz hastalığı geliştiği gözlendi. İnsidans hızı 515/100.000 olarak hesaplandı. Bunların %69’u pulmoner, %31’i ekstrapulmoner tutulum olduğu gözlendi. Bu hastalarda, aktif tüberküloz hastalığı gelişme süresi 28 ay olarak saptandı. Hastaların %69’u TNF-alfa blokörü, %15’i IL-6 inhibitörü, %0,07’si JAK inhibitörü ve %0,07’si CD20 monoklonal antikor inhibitörü kullanmıştı. Hastanemizde biyolojik ajanlarla tedavi alan hastalarda tüberküloz insidans hızı halen yüksektir. Bu hastaların izlemlerinde tedavi öncesi latent tüberküloz yönünden detaylı değerlendirme ve tedavi süreçlerinde aktif tüberküloz gelişimi yönünden yakın takip ve tarama gereklidir.

  • Open Access

    Diagnostic Performance of Sarcopenia Screening Tests in Chronic Lung Disease Patients

    by Aslı Görek Dilektaşlı, Demet Kerimoğlu, Ayten Odabaş, Abdurrahman Doğan, Arzu Özpehlivan, Nilüfer Aylin Acet Öztürk, Özge Aydın Güçlü, Ezgi Demirdöğen, Funda Coşkun, Ahmet Ursavaş, et al.

    Objective: Sarcopenia, the gradual decline in skeletal muscle mass (SMM), strength, and functionality, has negative health consequences such as premature death and disability. It is prevalent in chronic lung disease (CLD). Timely recognition of sarcopenia is required for focused therapy. This study sought to analyze the rate of sarcopenia in patients with CLD and to assess the diagnostic accuracy of the sarcopenia screening tests: the SARC-F, SARC-CalF, and Ishii tests. Materials and Methods: This study comprised individuals diagnosed with CLD and referred for pulmonary rehabilitation. Sarcopenia was evaluated based on the European Working Group on Sarcopenia in Older People criteria (EWGSOP and EWGSOP2), utilizing handgrip strength, SMM index, and gait speed. The diagnostic accuracy of screening tests (SARC-F, SARC-CalF, and Ishii) was assessed by sensitivity, specificity, and the area under the curve (AUC) in the Receiver Ooperating Ccharacteristics. Results: A total of 227 patients, with a mean age of 59.00 Å} 13.98 years, of whom 50.7% had chronic obstructive pulmonary disease (COPD), were included. The rate of probable sarcopenia was 41.2%, confirmed sarcopenia 2.5%, and severe sarcopenia 0.5%. The Ishii test exhibited the highest sensitivity (71.59%) and specificity (90.48%) for probable sarcopenia (AUC: 0.810); it also showed 100% sensitivity and substantial specificity (78.57%, AUC: 0.893) for confirmed sarcopenia. Conclusion: Sarcopenia is highly prevalent in CLD patients, underscoring the need for routine screening. Among the screening tools, the Ishii test exhibited the highest diagnostic accuracy, making it a valuable tool for early detection. Routine assessment and targeted interventions for sarcopenia could improve functional outcomes in CLD patients. Cite this article as: Dilektasli AG, Kerimoğl D, Odabaş A, et al. Diagnostic performance of sarcopenia screening tests in chronic lung disease patients. Eurasian J Med. 2025;57(1), 0806, doi: 10.5152/eurasianjmed.2025.25806.


  • Open Access

    Elevated neutrophil-to-lymphocyte ratio is associated with poor outcomes in patients with chronic thromboembolic pulmonary hypertension

    by Nilüfer Aylin Acet Öztürk, Şeyda Günay Polatkan, Özge Aydın Güçlü, Orkun Eray Terzi, Arzu Özpehlivan, Murat Biçer, Ahmet Sami Bayram, Yavuz Pehlivan, Belkıs Nihan Coşkun, Dilek Yeşilbursa, et al.

    BACKGROUND AND AIM: Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by pulmonary artery obstruction due to persistent organized thrombus and remodeling of pulmonary vascular structures. The treatment of CTEPH is considered a multimodal approach, including pulmonary endarterectomy (PEA) surgery, balloon pulmonary angioplasty, and medical therapy. We aimed to report our 12-year experience with CTEPH patients and identify risk factors for mortality in a real-life setting. METHODS: Patients older than 18 years, evaluated by a multidisciplinary expert team between July 1, 2011 and July 1, 2023, and diagnosed with CTEPH, were included in the study. RESULTS: The study population comprised 32 CTEPH patients with a mean age of 61.0±13.8 years and a median follow-up duration of 28 months. At the end of the follow-up period, 13 (40.6%) patients had died. A high neutrophil-to-lymphocyte ratio (NLR) and elevated B-type natriuretic peptide (BNP) levels at the time of diagnosis, along with low BNP levels and pulmonary artery pressure (PAP) changes within the first year, were observed in patients with mortality. Survival analysis, including NLR, BNP, pulmonary endarterectomy, and hematocrit (Hct) demonstrated that a high NLR and the absence of surgical treatment were independently associated with mortality. CONCLUSIONS: Our study underscores the critical role of PEA surgery in treatment of CTEPH, in addition to the importance of BNP trajectories and the neutrophil-to-lymphocyte ratio as prognostic biomarkers. Further research is needed to evaluate the reliability of easily obtained measurements, such as NLR, in categorizing high-risk patients.